Behcet Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Direct
37 Pages - GMD20008
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Drugs In Development, 2022, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.

Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 2 respectively.

Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Behcet Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Behcet Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Behcet Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Behcet Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Behcet Disease - Overview
Behcet Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Behcet Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Behcet Disease - Companies Involved in Therapeutics Development
Amgen Inc
Aristea Therapeutics Inc
Iltoo Pharma
Kangpu Biopharmaceuticals Ltd
Pharmapraxis
Behcet Disease - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
History of Events
apremilast - Drug Profile
Product Description
Mechanism Of Action
History of Events
KPG-612 - Drug Profile
Product Description
Mechanism Of Action
RIST-4721 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Behcet Disease - Dormant Projects
Behcet Disease - Discontinued Products
Behcet Disease - Product Development Milestones
Featured News & Press Releases
Feb 27, 2020: CHMP recommended extensions of indication for Otezla
Jul 19, 2019: FDA approves OTEZLA (apremilast) for the treatment of oral ulcers associatd with Behcet’s Disease
Feb 17, 2018: OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behcet's Disease with Oral Ulcers
Apr 15, 2015: Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine
Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behçet’s Disease At EULAR
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Behcet Disease, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Behcet Disease - Pipeline by Amgen Inc, 2022
Behcet Disease - Pipeline by Aristea Therapeutics Inc, 2022
Behcet Disease - Pipeline by Iltoo Pharma, 2022
Behcet Disease - Pipeline by Kangpu Biopharmaceuticals Ltd, 2022
Behcet Disease - Pipeline by Pharmapraxis, 2022
Behcet Disease - Dormant Projects, 2022
Behcet Disease - Discontinued Products, 2022

List of Figures
Number of Products under Development for Behcet Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838